Cardiff Oncology, Inc.
corporate_fare Company Profile
Cardiff Oncology, Inc. (NASDAQ:CRDF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for CRDF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CRDF spans 8-K, 10-Q, DEF 14A, 4.
Recent high-impact activity:
- FDA Grants Fast Track to Onvansertib in First-Line RAS-Mutated Colorectal Cancer
- Cardiff Q3: Onvansertib PFS Still Not Reached at 21+ Months; Phase 3 Slated for Q1 2027
- Cardiff Oncology Q3: Cash Falls to $33.8M, Going Concern Reiterated as Phase 3 Looms
- Cardiff Posts $30.4M Nine-Month Loss; Phase 3 Slips to Q1 2027 Pending Financing
- Cardiff Oncology CMO Exits as Interim Replacement Takes Over Ahead of Phase 3
Financial Snapshot
Short Interest & Short Volume
30.82 days to coverFINRA reported short interest of 12,261,903 shares in CRDF as of the October 30, 2026 settlement, a 1.2% increase from the prior period — about 30.8 days to cover at its recent average daily volume. On November 20, 2026, 42.9% of CRDF volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CRDF, detected from its recent SEC filings · based on capital-structure filings through 2026-07-16.
$10.05M Registered Direct Offering · Priced at Premium to Market
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →